NCT06193369 Digital Peer Navigation for Adolescents and Young Adults With Cancer
| NCT ID | NCT06193369 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Lymphoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 138 participants |
| Start Date | 2024-08-27 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 138 participants in total. It began in 2024-08-27 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Adolescents and young adults (AYA) diagnosed with cancer experience unique challenges after completing treatment and face distinct barriers to optimal care and support. These challenges include higher levels of symptom burden and treatment complications, interrupted education, careers and relationships, and financial hardship. AYA lack access to peers, relevant information and emotional support, and report gaps in care when dealing with these difficult challenges. Digital peer navigation could help to address the needs of AYA and overcome barriers to care and support. The PI developed True North Peer Navigation (TrueNTH-PN), an evidence-based digital peer navigation program for men with prostate cancer and online peer navigator training course. The goal of this project is to adapt TrueNTH-PN for AYA and evaluate its feasibility to overcome barriers to care and support, and enhance patient activation among AYA during the challenging post-treatment phase. In partnership with AYA cancer survivors, the Canadian Cancer Society, Young Adult Cancer Canada, a digital app design firm and technology provider, our cross-Canada team will: (1) Adapt and evaluate the usability of the TrueNTH-PN app for AYA; (2) Adapt and evaluate the effectiveness of the Peer Navigator Training Course for AYA; and (3) Determine the feasibility, acceptability and preliminary effectiveness of the new AYA-PN program among post-treatment AYA cancer survivors. This project will produce an innovative solution to an important service gap in the lives of AYA with cancer. It has the potential to address the support needs of AYA, overcome barriers to care, and empower AYA to take proactive role in managing their health. In addition, it will give rise to AYA peer navigators with specialized skills, which could fill gaps in disrupted education and career paths, and help to attain future goals.
Eligibility Criteria
Inclusion criteria: 1. Are 18-40 years old; 2. Were diagnosed with breast or testicular cancer, lymphoma or sarcoma between the ages of 15-39 years old; 3. Have completed therapy within the last 12 months; 4. Are comfortable using the internet; 5. Have an active email address OR are willing to create one; 6. Able to read and speak English. Exclusion criteria: 1. Have metastatic disease or are receiving palliative end-of-life care; 2. Are not willing to be randomized.
Contact & Investigator
Jackie Bender, PhD
PRINCIPAL INVESTIGATOR
UHN
Frequently Asked Questions
Who can join the NCT06193369 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06193369 currently recruiting?
Yes, NCT06193369 is actively recruiting participants. Contact the research team at Jackie.Bender@uhn.ca for enrollment information.
Where is the NCT06193369 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT06193369 clinical trial?
NCT06193369 is sponsored by University Health Network, Toronto. The principal investigator is Jackie Bender, PhD at UHN. The trial plans to enroll 138 participants.